Opinion

Video

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

Author(s):

Catherine C. Coombs, MDMatthew S. Davids, MD, MMSc

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

Video content above is prompted by the following:

  • BGB-16673
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Marc Machaalani, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Kimmie Ng, MD, MPH
Kathleen A. Dorritie, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Saro H. Armenian, DO, MPH
Related Content
Andrew Hantel, MD, faculty member, Divisions of Leukemia and Population Sciences, Dana-Farber Cancer Institute
October 9th 2024

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Cigall Kadoch, PhD
October 7th 2024

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Andrew Hantel, MD
October 4th 2024

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

Grzegorz S. Nowakowski, MD, consultant, Division of Hematology, enterprise deputy director, Clinical Research, Mayo Clinic Comprehensive Cancer Center
October 4th 2024

Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm